# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the b...
AbbVie Inc. has good dividend yield and attractive valuations, according to Jim Lebenthal of Cerity Partners.
AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a...
PICCOLO trial met its primary endpoint of objective response rate (ORR)Data from the study will be presented at a future medica...
ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multip...